Category: by reason for retraction

Caught Our Notice: What if you find out a paper relied on expired herbal supplement?

Via Wikimedia

Title: Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA- transcription factor-target gene network

What Caught Our Attention: The researchers were studying how curcumin, a component of the spice turmeric, can inhibit lung cancer metastases. But upon learning that the primary material had been expired at the time of testing (and realizing they were unable to repeat their experiments), the researchers pulled their paper. Expiration dates do have safety factors built in, but attention to such details is imperative in research.  Continue reading Caught Our Notice: What if you find out a paper relied on expired herbal supplement?

Journal bans author for three years after retracting paper with “serious ethical” problems

An anatomy journal has banned a researcher from submitting papers for three years after determining one of his recently published papers suffered from “serious ethical” issues.

According to Jae Seung Kang, associate editor at the journal Anatomy and Cell Biology (ACB), the paper’s sole author—Jae Chul Lee—falsified both his affiliation and approval for conducting animal experiments in the paper, published online in March.

Kang said the journal discovered the issues after Lee submitted other papers to the journal this past August. During the journal’s review process, it discovered “over 70% redundancy”—ie, plagiarism—between the newly submitted papers and two now-retracted papers—the ACB paper as well as a 2015 paper published in the Journal of Pathology and Translational Medicine, on which Jae Chul Lee was corresponding author. The issues prompted the journal to conduct “an in-depth investigation,” Kang said. Continue reading Journal bans author for three years after retracting paper with “serious ethical” problems

Caught Our Notice: Don’t count your chicken (genes) before they’re hatched

Via Wikimedia

Title: Molecular Characterization and Biological Activity of Interferon-α in Indian Peafowl (Pavo cristatus)

What Caught Our Attention: Soon after the paper appeared, the journal was alerted to the fact its findings were at odds with others in the field. When the editor approached the authors, everything fell apart: The authors couldn’t repeat the experiments, and “were also unsure of the molecular probes that were used in the study.” While it isn’t unusual to have doubts about data — since since research is a process of experimentation — it is odd not to know how your experiment was conducted. The paper was retracted less than two months after it was published. The manuscript was accepted two months after it was submitted in early May, theoretically giving reviewers enough time to catch these issues (along with the authors’ failure to cite relevant papers).  

Continue reading Caught Our Notice: Don’t count your chicken (genes) before they’re hatched

Scientist to chemistry journal: “Plse retract this ms ASAP”

The presence of allegedly obvious manipulations in a 2017 chemistry paper has prompted a reader outcry.

Over the last couple of days, a user on PubPeer and others on Twitter have accused the paper of containing clear duplications; the paper was already corrected in August, in which one scientist alleges the authors replaced “an obviously fabricated” figure with a “slightly better photo-shopped one.”

In response, the editor of ACS Biomaterials Science & Engineering, David Kaplan, told us:

Continue reading Scientist to chemistry journal: “Plse retract this ms ASAP”

Brazil research foundation sues scientist over $103k scholarship

The São Paulo Research Foundation (FAPESP), a state-level agency in Brazil that funds scientific research, is suing Paty Karoll Picardi, a protégé of Brazilian diabetes researcher Mario Saad.

According to a São Paulo Court of Justice website, the reason stated is for “recebimento of bolsa de estudos,“ which translates to “receipt of scholarship.” FAPESP is suing for 334,116 Brazilian Reals ($102,927).

Now, Picardi is counter-suing, according to a case document released Nov. 17 — although we’re not sure for what, and why.  Continue reading Brazil research foundation sues scientist over $103k scholarship

Caught Our Notice: 1,376 words of overlap in paper by food researcher Brian Wansink

Via Wikimedia

Title: Change Their Choice! Changing Behavior Using the CAN Approach and Activism Research

What Caught Our Attention: Food researcher Brian Wansink has had a rough time lately. After researchers began scrutinizing his work, he has racked up five retractions and multiple corrections. (We’re counting one retracted paper twice, as Wansink first retracted and replaced it with a new version, then retracted the replacement.)

These notices haven’t gone unnoticed, either by us or other media outlets — BuzzFeed reported on his most recent retraction this weekend, a paper a critic discussed with us, as well. Yesterday, BuzzFeed also reported that Cornell is investigating. (It wouldn’t be the first time — in April, Cornell announced that it had found evidence of mistakes, not misconduct, in Wansink’s papers.)  Below, we present his 13th correction, for duplicated text — 1,376 words of duplicated text, to be exact.

Continue reading Caught Our Notice: 1,376 words of overlap in paper by food researcher Brian Wansink

Where’s the data? Authors can’t support figures in 2017 kidney paper

Researchers have retracted a 2017 paper exploring a novel approach to treat kidney injury, because three images were “constructed inappropriately.”

That’s about as much as we know: The retraction notice provides few details about the nature of the issue, only that the authors—most of whom work at Pennsylvania State University College of Medicine in Hershey—could not provide the original data for the recently published figures.

The paper, published in American Journal of Physiology – Renal Physiology, was retracted October 1, just over four months after appearing online in mid-May. Continue reading Where’s the data? Authors can’t support figures in 2017 kidney paper

Caught Our Notice: To know if someone’s been vaccinated, just asking isn’t enough

Via Wikimedia

Title: Hepatitis B Virus Infection in Preconception Period Among Women of Reproductive Age in Rural China – A Nationwide Study

What Caught Our Attention: When researchers set out to study hepatitis B among women in rural China, and they wanted to know if the women had been vaccinated against the virus, they simply asked them. While that can sometimes be useful, apparently it was a mistake in this case, as the reliance on patient memory injected too much doubt into these findings.  Continue reading Caught Our Notice: To know if someone’s been vaccinated, just asking isn’t enough

Caught Our Notice: When authors go MIA, the article may follow

Via Wikimedia

Title: IRF9 inhibits human acute myeloid leukemia through the SIRT1-p53 signaling pathway

What Caught Our Attention: When authors fail to respond to editors’ requests for information, it isn’t hard to imagine that the submitted manuscript will lose its publishing appeal. In this case, the journal and publisher withdrew the article after “repeated attempts” to contact the authors were unsuccessful.

The notice doesn’t say why the journal needed to get in touch with the authors; of course, some authors may cease correspondence for a variety of reasons, but there is usually some backstory. Since the authors disappeared, the withdrawn article has, as well. Continue reading Caught Our Notice: When authors go MIA, the article may follow

US court issues injunction against OMICS to stop “deceptive practices”

A US government agency has won an initial court ruling against OMICS, which the government says will help stop the academic publisher’s deceptive business practices.

Today, the Federal Trade Commission (FTC) announced that it won a preliminary injunction in September in its lawsuit against Srinubabu Gedela, CEO of OMICS Group and other companies.

The lawsuit, filed in August 2016, accused the defendants — which include Gedela and OMICS Group, iMedPub, and Conference Series — of deceptive business practices related to journal publishing and scientific conferences. The FTC alleged the defendants used the names of prominent researchers to draw conference attendees, even though the researchers had not agreed to participate; misled readers about whether articles had been peer reviewed; failed to provide authors with transparent information about publishing fees prior to submission; and presented misleading “impact factors” for journals.

On Sept. 29, Judge Gloria Navarro of the US District Court for the District of Nevada, wrote that evidence submitted by the FTC “is sufficient to support a preliminary conclusion that Defendants made misrepresentations regarding their journal publishing” and conferences, and: Continue reading US court issues injunction against OMICS to stop “deceptive practices”